Blueprint Medicines (BPMC) Tops Q4 EPS by 1c

Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($0.75), $0.01 better than the analyst estimate of ($0.76). Revenue for the quarter came in at $7.7 million versus the consensus estimate of $5.87 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Winnebago Industries (WGO) PT Lowered to $40 at Benchmark on Pressured NT Demand
• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold